Stryker Co. (NYSE:SYK) Shares Bought by Dynasty Wealth Management LLC

Dynasty Wealth Management LLC grew its stake in Stryker Co. (NYSE:SYK) by 9.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 7,611 shares of the medical technology company’s stock after acquiring an additional 633 shares during the period. Dynasty Wealth Management LLC’s holdings in Stryker were worth $2,740,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Dunhill Financial LLC lifted its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the 4th quarter worth $30,000. BankPlus Trust Department acquired a new position in Stryker during the fourth quarter worth $33,000. Darwin Wealth Management LLC purchased a new position in Stryker during the 3rd quarter valued at about $36,000. Finally, Activest Wealth Management acquired a new stake in Stryker during the 4th quarter valued at $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Stock Down 0.7 %

Shares of SYK stock opened at $389.10 on Friday. The stock has a 50 day moving average of $380.06 and a 200-day moving average of $370.50. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm has a market cap of $148.47 billion, a PE ratio of 50.14, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business earned $3.46 EPS. On average, equities analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s dividend payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. Wells Fargo & Company upped their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Stifel Nicolaus lifted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Truist Financial increased their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Canaccord Genuity Group increased their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.